IMF Videos Search Content For Care Partner (351) Patient (347) Healthcare Provider (213) Healthcare Professional (210) Series - Any - About the IMF (2) ASCO/EHA (71) ASH (102) Ask Dr. Durie (149) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (22) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (185) Financial Considerations (15) Frontline Therapy (83) Health Equity (34) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (69) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (56) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (42) Recorded Seminars & Workshops (15) Recorded Webinars (24) Relapse/Refractory Myeloma (136) Research Updates (193) Symptom Management (114) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (147) High-Risk Myeloma (96) High-risk Smoldering Myeloma (70) Late Relapse (4–6 Lines of Therapy) (158) MGUS (85) Newly Diagnosed (Pre-Treatment or First Treatment) (158) Smoldering Myeloma (109) Types of Therapy Immunomodulatory drugs (IMiDs) (94) Immunotherapies (CAR T; BiTE, etc.) (161) Monoclonal antibodies (78) Proteasome inhibitors (66) Stem cell transplant (84) Steroids (63) Supportive Care (152) Year Published 2026 (44) 2025 (107) 2024 (93) 2023 (92) 2022 (36) 2021 (31) 2020 (13) 2019 (36) 2018 (21) 2017 (30) 2016 (24) 2015 (30) Trusted Voices Dr. Brian GM Durie (144) Dr. Joseph Mikhael (103) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (29) Dr. María-Victoria Mateos (7) Donna Catamero, ANP-BC, OCN, CCRC (5) Dr. Saad Usmani (4) Dr. Sigurður Kristinsson (4) Dr. Urvi A. Shah (4) Dr. Shaji Kumar (3) Dr. S. Vincent Rajkumar (1) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Heather Cooper Ortner (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)? January 19, 2023 Ask Dr. Durie Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States January 16, 2023 ASH Bispecifics Part 4: The Science of Bispecific Antibodies January 13, 2023 Emerging Therapies Bispecifics Part 3: The Pros and Cons of Bispecifics January 13, 2023 Emerging Therapies Bispecifics Part 2: Monoclonal and Bispecific Antibodies January 13, 2023 Emerging Therapies Bispecifics Part I: Immune System and Immunotherapy Basics January 13, 2023 Emerging Therapies Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1 January 12, 2023 ASH KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in High Risk Multiple Myeloma Pts with Early Relapse after ASCT January 12, 2023 ASH Do patients with MGUS need to have a bone marrow test? January 12, 2023 Ask Dr. Durie Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma January 10, 2023 ASH MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study January 2, 2023 ASH Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort January 2, 2023 ASH Load More
